ATE350032T1 - Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen - Google Patents

Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen

Info

Publication number
ATE350032T1
ATE350032T1 AT99932296T AT99932296T ATE350032T1 AT E350032 T1 ATE350032 T1 AT E350032T1 AT 99932296 T AT99932296 T AT 99932296T AT 99932296 T AT99932296 T AT 99932296T AT E350032 T1 ATE350032 T1 AT E350032T1
Authority
AT
Austria
Prior art keywords
inhibitors
pain
protein kinase
epsilone
epsilon
Prior art date
Application number
AT99932296T
Other languages
English (en)
Inventor
Robert O Messing
Jon D Levine
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE350032T1 publication Critical patent/ATE350032T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99932296T 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen ATE350032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9175598P 1998-07-06 1998-07-06
US10376398P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
ATE350032T1 true ATE350032T1 (de) 2007-01-15

Family

ID=26784298

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99932296T ATE350032T1 (de) 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen

Country Status (10)

Country Link
EP (1) EP1093379B1 (de)
JP (1) JP2002519391A (de)
AT (1) ATE350032T1 (de)
AU (1) AU764760B2 (de)
CA (1) CA2336709A1 (de)
DE (1) DE69934689T2 (de)
ES (1) ES2283120T3 (de)
IL (1) IL140716A0 (de)
NZ (1) NZ508767A (de)
WO (1) WO2000001415A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335220B2 (en) 2004-11-05 2008-02-26 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
JP2005527209A (ja) 2002-04-22 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
WO2004103266A2 (en) * 2003-05-16 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
EP2228069A1 (de) * 2003-09-16 2010-09-15 Garvan Institute Of Medical Research Antagonisten der Protein Kinase C-Epsilon (pkcepsilon) und deren Anwendungen für die Behandlung von damit im Zusammenhang stehenden aberranten Glukosestoffwechsel
WO2006095086A2 (fr) * 2005-03-07 2006-09-14 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
JP2008537880A (ja) * 2005-04-02 2008-10-02 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 調節化合物及び免疫応答を測定するためのアッセイ
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
EP2177510A1 (de) 2008-10-17 2010-04-21 Universität des Saarlandes Allosterische Proteinkinasemodulatoren
JP2010090176A (ja) * 2010-01-26 2010-04-22 Board Of Trustees Of The Leland Stanford Junior Univ 離脱症状における使用のためのプロテインキナーゼｃペプチド
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2014081029A1 (ja) * 2012-11-26 2014-05-30 学校法人近畿大学 抗がん剤による末梢神経障害の予防、治療、または軽減剤
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
WO1997015575A1 (en) * 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.

Also Published As

Publication number Publication date
DE69934689D1 (de) 2007-02-15
CA2336709A1 (en) 2000-01-13
DE69934689T2 (de) 2007-10-25
EP1093379A2 (de) 2001-04-25
ES2283120T3 (es) 2007-10-16
WO2000001415A3 (en) 2000-04-13
IL140716A0 (en) 2002-02-10
AU4863199A (en) 2000-01-24
EP1093379B1 (de) 2007-01-03
JP2002519391A (ja) 2002-07-02
NZ508767A (en) 2003-12-19
AU764760B2 (en) 2003-08-28
WO2000001415A2 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
MX9803563A (es) Preparacion terapeutica para la administracion transdermica de principios activos.
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
WO1998033491A3 (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
AU4923093A (en) Inhibitors of metazoan parasite proteases
BRPI0411364A (pt) compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE59910944D1 (de) Transdermales therapeutisches system zur anwendung von candesartan
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties